show episodes
 
We believe in the educational merits of Free Open Access Medical education (FOAM), which includes podcasts, blogs, articles on PubMed Central, conferences streamed for free and more. As a result, we would like to encourage others to move beyond quoting podcasts and into the realm of tying “cutting edge” FOAM to the core content. We’ll provide some review and references for listeners to go read. Why, indeed, should we FOAM it alone when FOAM can inspire us to go, read, think, and be excellent?
 
Loading …
show series
 
In this episode, we discuss ivermectin as a potential therapeutic for COVID-19 and review available randomized trials evaluating this drug. Chaccour et al E-Clinical Medicine Lopez-Medina et al. JAMA Schwartz et al (not yet published) IDSA guidelines NIH Treatment guidelines Show notes: FOAMcast.org Thanks for listening! Jeremy Faust and Lauren Wes…
 
There's been a lot of excitement over various drugs for COVID-19, including anti-inflammatory drugs. Colchicine, a medication long used for gout, fits that bill. In this podcast, we review 3 trials of colchicine including COLCORONA, GRECCO-19, and a study by Lopes et al. Show notes: FOAMcast.org Thanks for listening! Jeremy Faust and Lauren Westafe…
 
Early studies of tocilizumab, a monoclonal antibody that binds interleukin-6 , were disappointing. However, the REMAP-CAP trial recently reported a benefit to tocilizumab in non-critically ill hospitalized patients with COVID-19. Now, from the RECOVERY trial (the trial that brought us dexamethasone), we have more good news for tocilizumab - which w…
 
Prior randomized trials of convalescent plasma in COVID-19 have had disappointing results. However, these trials included patients with severe illness who were many days (if not weeks) into the course of their illness. To date, it was hypothesized, but unknown, that the benefit would be in patients very early in the course of their illness. We cove…
 
In this quick literature update we review the new recommendations from the CDC for the treatment of gonococcal infections which include: Higher dose ceftriaxone (500 mg IM) or 1 gm IM if ≥150 kg patient No routine azithromycin Preference for doxycycline for co-treatment of presumed chlamydial infection Show notes and references: FOAMcast.org Thanks…
 
For years studies have questioned whether pulse oximeters perform as well in non-White patients as in White patients. This is particularly important now as disposition decisions in patients with COVID-19 are often made based on pulse oximetry readings. We discussed an article by Sjoding et al in NEJM Show notes at FOAMcast.org Thanks for listening!…
 
Despite multiple Phase II/III vaccine trials of >30,000 participants, pregnant patients or those who are lactating have been largely excluded. In this podcast, we cover what we know (and what we don't know thus far). The Pfizer BNT162b2 trial data submitted for FDA Emergency Use Authorization does include information on a minuscule number of patien…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* Vaccines for SARS-CoV-2 have been in development for only a few months, but several have published early results from Phase…
 
In this episode, we review cannabinoid hyperemesis syndrome and two recent randomized controlled trials on treatments Haloperidol - Ruberto et al (Annals of Emergency Medicine, In Press) Capsaicin - Dean et al. Acad Emerg Med 2020. Show notes (references, graphics) at FOAMcast.org Thanks for listening! Jeremy Faust and Lauren Westafer…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* Monoclonal antibodies have received significant attention over the past month and we previously podcasted on antibodies tha…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* Monoclonal antibodies have received significant attention over the past couple of weeks. In this episode, we review what we…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* We review a retrospective evaluation of COVID-19 infections in employees after a protocol that increased the use of high fl…
 
We spoonfeed you a new article on risk stratification of pulmonary embolism (with critical appraisal pearls!) In this episode, we review a new trial by Barnes et al on antacids versus antacids with lidocaine for epigastric pain and dyspepsia Show notes and references at FOAMcast.org Thanks for listening, Lauren Westafer and Jeremy Faust…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* We review a new meta-analysis from the WHO REACT group of steroids in critically ill patients with COVID-19 and 3 new rando…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* We review the evidence, to date, on convalescent plasma for the treatment of COVID-19. This includes 3 randomized trials, a…
 
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear* We review Spinner et al in JAMA 2020, an open label trial of remdesivir 5 days vs remdesivir 10 days vs 'standard of care' …
 
Introducing a new series of quick, spoonfed literature updates, 1 article at a time In this episode we review a new trial by Warren et al on antacids versus antacids with lidocaine for epigastric pain and dyspepsia Show notes and references at FOAMcast.org Thanks for listening, Lauren Westafer and Jeremy Faust…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login